-

Palleon Pharmaceuticals Announces IND Clearance for First-in-Class Cancer Immunotherapy Leveraging Glyco-Immunology

- Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumors -

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration has cleared the company’s investigational new drug (IND) application for its lead candidate E-602. This clearance paves the way for Palleon’s first-in-class cancer immunotherapy which targets immunosuppressive sialoglycans to enter clinical testing.

“We are proud to have reached this milestone in advancing glyco-immunology from a promising, nascent scientific field to an entirely new class of medicines,” said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. “We continue to leverage our unrivaled expertise in glycobiology drug discovery and development to expand our product pipeline in the pursuit of better therapies for patients with cancer and inflammatory diseases.”

E-602 is a first-in-class engineered human sialidase enzyme genetic fusion from Palleon’s EAGLE platform which is designed to desialylate both immune cells and tumor cells, potentiating an anti-tumor immune response. Palleon’s Phase 1/2 trial of E-602 is expected to begin enrolling patients with solid tumors refractory to standard of care in Q1 2022.

About Palleon Pharmaceuticals

Palleon Pharmaceuticals is the leading biotechnology company developing drugs that harness glyco-immunology to treat cancer and inflammatory diseases. The company’s proprietary platforms overcome scientific hurdles that limited progress in the glycobiology field to create novel therapeutics for devastating diseases characterized by immune system dysfunction. Palleon’s lead program in oncology, E-602, is an enzymatic degrader of immunosuppressive sialoglycans on tumors and immune cells which is expected to enter clinical testing in refractory cancer patients in early 2022. www.palleonpharma.com.

Contacts

Palleon Media Contact
Thomas Stephenson
Ten Bridge Communications
thomas@tenbridgecommunications.com
(617) 448-1803

Palleon Pharmaceuticals


Release Versions

Contacts

Palleon Media Contact
Thomas Stephenson
Ten Bridge Communications
thomas@tenbridgecommunications.com
(617) 448-1803

More News From Palleon Pharmaceuticals

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ACR Convergence 2026

WATERTOWN, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced early proof-of-concept data for its first-in-class sialidase-Fc fusion protein HLX79/E-602 (efgitasialase alfa) in primary membranous nephropathy (pMN). The results were presented in an oral session at the American College of Rheumatology (ACR) Convergence 2026 in Orlando. Palleon’s partner, Shanghai Henlius...

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026

WATERTOWN, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced Phase 2 results for HLX79/E-602 (efgitasialase alfa), a first-in-class sialidase-Fc fusion protein, in primary membranous nephropathy (pMN). The data were presented today in a late-breaking oral session at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver. The randomized Phase 2 trial (NCT07...

Palleon Pharmaceuticals Announces Oral Presentation of Interim Phase 2 trial data for HLX79/E-602 in Membranous Nephropathy at the 2026 American College of Rheumatology (ACR) Convergence

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing novel therapeutics for autoimmunity and cancer, will deliver an oral presentation at the 2026 American College of Rheumatology (ACR) Convergence, taking place November 6-11 in Orlando, Florida. Palleon's presentation will take place on Wednesday, November 11. Details of Palleon's Presentation: American College of Rheumatology (ACR) Convergence Title: Rapid and deep clinical responses to H...
Back to Newsroom